Company news

Silexion Therapeutics Corp news in 2026

Silexion Therapeutics Corp's news releases, calls and decks from 2026, newest first.

View company

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

September 30, 2026

Silexion Therapeutics Announces Exercise of Warrants

September 29, 2026

Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers

September 28, 2026

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences

September 9, 2026

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 14, 2026

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

August 11, 2026

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

August 4, 2026

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

July 28, 2026

Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)

July 28, 2026

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

June 22, 2026

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

May 26, 2026

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 18, 2026

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

May 15, 2026

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

May 13, 2026

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

May 12, 2026

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

April 28, 2026

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

March 23, 2026

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 16, 2026

Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting

March 5, 2026

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

January 21, 2026

Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026

January 6, 2026

Decks in 2026